C6O — Clovis Oncology Income Statement
0.000.00%
Last trade - 00:00- €2.17m
- €538.48m
- $148.76m
Annual income statement for Clovis Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 55.5 | 95.4 | 143 | 165 | 149 |
| Cost of Revenue | |||||
| Gross Profit | 43.8 | 73.3 | 108 | 123 | 110 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 399 | 457 | 528 | 505 | 377 |
| Operating Profit | -343 | -362 | -385 | -341 | -228 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -350 | -367 | -399 | -370 | -265 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -184 | -368 | -400 | -369 | -265 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -346 | -368 | -400 | -369 | -265 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -346 | -368 | -400 | -369 | -265 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.46 | -6.72 | -7.16 | -4.08 | -2.23 |